# Sirolimus-Based Immunosuppression Therapy in OLT for Patients With HCC Exceeding Milan Criteria

> **NCT00554125** · PHASE3 · UNKNOWN · sponsor: **Fudan University** · enrollment: 220 (estimated)

## Conditions studied

- Hepatocellular Carcinoma

## Interventions

- **DRUG:** sirolimus

## Key facts

- **NCT ID:** NCT00554125
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2007-08
- **Primary completion:** —
- **Final completion:** 2013-08
- **Target enrollment:** 220 (ESTIMATED)
- **Last updated:** 2007-11-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00554125

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00554125, "Sirolimus-Based Immunosuppression Therapy in OLT for Patients With HCC Exceeding Milan Criteria". Retrieved via AI Analytics 2026-07-09 from https://api.ai-analytics.org/clinical/NCT00554125. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*